Investigation of infection with Campylobacter jejuni in a man with hypogammaglobulinaemia using PCR-single-strandedconformational polymorphism (PCR-SSCP) typing

Moore, John E.; Curran, Martin D.; Wareing, D. R. A.; Boyd, N. A. M.; Glynn, G.; Millar, B. Cherie; Daly, G.; Murphy, Philip G.

doi:10.1078/1438-4221-00099

Cited by 8 publications

(9 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of these, six patients had common variable immunodeficiency (CVID) [22][23][24][25], four had X-linked hypogammaglobulinemia (XLA) [26][27][28][29], and two had immunodeficiency with thymoma (Good syndrome) [24,30]. In two cases, the nature of hypogammaglobulinemia was not reported [31,32] but was likely primary, as no secondary causes were reported, and because thrombocytopenia and autoimmune hemolytic anemia suggested CVID in one of these patients [32]. No published cases of recurrent Campylobacter infection in the setting of secondary hypogammaglobulinemia were found.…”

Section: Literature Reviewmentioning

confidence: 99%

Section: Literature Reviewmentioning

confidence: 99%

“…In 8 of the 14 patients, bacteremia was also recorded [25][26][27][28][29][30][31]. All patients received at least one course of antibiotics except for one case where therapy was not mentioned [31]. In seven patients, IVIG replacement therapy [24,26,[28][29][30]32] was recorded before recurrent Campylobacter enteritis was noted; in six cases, IVIG was not mentioned [22,23,27,28,31], and in one case it was started after hypogammaglobulinemia was diagnosed because of recurrent Campylobacter infections [25].…”

Section: Literature Reviewmentioning

confidence: 99%

“…All patients received at least one course of antibiotics except for one case where therapy was not mentioned [31]. In seven patients, IVIG replacement therapy [24,26,[28][29][30]32] was recorded before recurrent Campylobacter enteritis was noted; in six cases, IVIG was not mentioned [22,23,27,28,31], and in one case it was started after hypogammaglobulinemia was diagnosed because of recurrent Campylobacter infections [25]. In seven patients, diarrhea was resolved [24][25][26]30,32], while in six patients, including our patient, symptoms improved [22,23,28,29].…”

Section: Literature Reviewmentioning

confidence: 99%

See 3 more Smart Citations

Recurrent Campylobacter Enteritis in Patients with Hypogammaglobulinemia: Review of the Literature

Najjar

Paluca

Loukidis

et al. 2020

JCM

View full text Add to dashboard Cite

Recurrent Campylobacter enteritis is a well-recorded complication of primary hypogammaglobulinemia but has only rarely been reported with other types of immunodeficiency, and no cases have been reported after rituximab-associated secondary hypogammaglobulinemia. We therefore reviewed our local microbiology laboratory databases and conducted a literature search, to provide a detailed characterization of the immunodeficiency states associated with recurrent Campylobacter enteritis. Published cases had primary hypogammaglobulinemia, most frequently in the setting of common variable immunodeficiency, x-linked agammaglobulinemia, and Good syndrome. No cases were identified in the literature after rituximab or secondary hypogammaglobulinemia. We report a 73-year-old patient with recurrent Campylobacter enteritis and hypogammaglobulinemia in the setting of non-Hodgkin lymphoma, chemotherapy, and maintenance rituximab. Physicians should be aware of the association of recurrent Campylobacter enteritis and immunodeficiency, most commonly in primary hypogammaglobulinemia. Rituximab alone may not be sufficiently immunosuppressive for recurrent campylobacteriosis to occur; additional factors, including hematological malignancy and its treatment, appear necessary. Patients with recurrent Campylobacter enteritis and those starting rituximab should be investigated for hypogammaglobulinemia and B-lymphopenia.

show abstract

Section: Literature Reviewmentioning

confidence: 99%

Section: Literature Reviewmentioning

confidence: 99%

Section: Literature Reviewmentioning

confidence: 99%

Section: Literature Reviewmentioning

confidence: 99%

See 2 more Smart Citations

Recurrent Campylobacter Enteritis in Patients with Hypogammaglobulinemia: Review of the Literature

Najjar

Paluca

Loukidis

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…We theorized that the incomplete protection may be due to the fact that protective immunity against H. pylori following vaccination is not mediated by antibodies (4,13,34). We therefore extended this study by selecting a bacterial infection (C. jejuni infection) where humoral immunity is believed to be protective (2,25,36). In mice, C. jejuni colonizes the mouse intestine for a period of 2 to 3 weeks before being naturally cleared (36).…”

Section: Uea-i-targeted Vaccination Of Mice Against the Intestinal Pamentioning

confidence: 99%

M-Cell Targeting of Whole Killed Bacteria Induces Protective Immunity against Gastrointestinal Pathogens

et al. 2009

View full text Add to dashboard Cite

As the majority of human pathogens infect via a mucosal surface, delivery of killed vaccines by mucosal routes could potentially improve protection against many such organisms. Our ability to develop effective killed mucosal vaccines is inhibited by a lack of adjuvants that are safe and effective in humans. The Ulex europaeus agglutinin I (UEA-I) lectin specifically binds M cells lining the murine gastrointestinal tract. We explored the potential for M-cell-targeted vaccination of whole, killed Helicobacter pylori, the main causative agent of peptic ulcer disease and gastric cancer, and Campylobacter jejuni, the most common cause of diarrhea. Oral delivery of UEA-I-agglutinated H. pylori or C. jejuni induced a significant increase in both serum and intestinal antibody levels. This elevated response (i) required the use of whole bacteria, as it did not occur with lysate; (ii) was not mediated by formation of particulate clumps, as agglutination with a lectin with a different glycan specificity had no effect; and (iii) was not due to lectin-mediated, nonspecific immunostimulatory activity, as UEA-I codelivery with nonagglutinated bacteria did not enhance the response. Vaccination with UEA-I-agglutinated, killed whole H. pylori induced a protective response against subsequent live challenge that was as effective as that induced by cholera toxin adjuvant. Moreover, vaccination against C. jejuni by this approach resulted in complete protection against challenge in almost all animals. We believe that this is the first demonstration that targeting of whole killed bacteria to mucosal M cells can induce protective immunity without the addition of an immunostimulatory adjuvant.

show abstract

Chronic or recurrent Campylobacter enteritis in primary immunodeficiency: A UK national case-series and review of the literature

Grammatikos

Thomas

Johnston

et al. 2023

The Journal of Allergy and Clinical Immunology: In Practice

View full text Add to dashboard Cite

Investigation of infection with Campylobacter jejuni in a man with hypogammaglobulinaemia using PCR-single-strandedconformational polymorphism (PCR-SSCP) typing

Cited by 8 publications

References 15 publications

Recurrent Campylobacter Enteritis in Patients with Hypogammaglobulinemia: Review of the Literature

Recurrent Campylobacter Enteritis in Patients with Hypogammaglobulinemia: Review of the Literature

M-Cell Targeting of Whole Killed Bacteria Induces Protective Immunity against Gastrointestinal Pathogens

Chronic or recurrent Campylobacter enteritis in primary immunodeficiency: A UK national case-series and review of the literature

Contact Info

Product

Resources

About